FATE THERAPEUTICS INCFATEEarnings & Financial Report

Nasdaq · pharmaceutical industry

Insys Therapeutics was an American specialty pharmaceutical company based in Chandler, Arizona in 1990. Its main product was Subsys, a sublingual liquid form of the drug fentanyl. Fentanyl is an extremely fast-acting and powerful opioid used to relieve breakthrough pain in cancer patients, and prescription of fentanyl in the US for such pain usually requires documented failure of more conservative therapies.

NextMar 19, 2026

Revenue

$1.7M

Gross Profit

N/A

Operating Profit

$-34.7M

Net Profit

$-32.3M

Gross Margin

N/A

Operating Margin

-1995.1%

Net Margin

-1852.4%

YoY Growth

-43.4%

EPS

$-0.27

Financial Flow

FATE THERAPEUTICS INC Q3 2025 Financial Summary

FATE THERAPEUTICS INC reported revenue of $1.7M for Q3 2025, with a net profit of $-32.3M (-1852.4% margin). Cost of goods sold was N/A, operating expenses totaled N/A.

Key Financial Metrics

Total Revenue	$1.7M
Net Profit	$-32.3M
Gross Margin	N/A
Operating Margin	-1995.1%
Report Period	Q3 2025

FATE THERAPEUTICS INC Annual Revenue by Year

FATE THERAPEUTICS INC annual revenue history includes year-by-year totals (for example, 2024 revenue was $13.6M).

Year	Annual Revenue
2024	$13.6M
2023	$63.5M
2022	$96.3M

Income Statement

	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Revenue	$1.7M	$1.9M	$6.8M	$3.1M	$1.9M	$1.6M	$1.9M	$1.7M
YoY Growth	-96.2%	-96.7%	625.8%	58.1%	11.0%	-15.4%	-71.8%	-43.4%

Balance Sheet

	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Assets	$506.2M	$569.9M	$528.8M	$495.0M	$440.7M	$398.7M	$371.6M	$343.7M
Liabilities	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Equity	$368.4M	$426.1M	$397.0M	$362.3M	$318.7M	$288.4M	$261.4M	$234.1M